# Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

> **NCT01435954** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 13551 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Early combination therapy
- **DRUG:** Delayed combination therapy

## Key facts

- **NCT ID:** NCT01435954
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 13551 (ACTUAL)
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435954, "Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01435954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*